Výsledky vyhledávání

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Autor: Oø Bruland, Michael W. Kattan, Svein Inge Helle, Sten Nilsson, L. Xu, Daniel Heinrich, Joe M. O'Sullivan, Robert E. Coleman, M. Shan, Oliver Sartor, Scott Wilhelm, Nicholas J. Vogelzang, S. Kobina, Chris Parker

Publikováno v: Annals of Oncology
Sartor, O, Coleman, R E, Nilsson, S, Heinrich, D, Helle, S I, O'Sullivan, J M, Vogelzang, N J, Bruland, Ø, Kobina, S, Wilhelm, S, Xu, L, Shan, M, Kattan, M W & Parker, C 2017, ' An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 ', Annals of Oncology . https://doi.org/10.1093/annonc/mdx044

Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not esta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94175b15a8f23ebd8074af9f1abd19d7
http://europepmc.org/articles/PMC5406754

Zobrazit plný text záznamu

Health economic assessments of anticancer agents: A comparison of assessment technologies applied to end-stage cancer

Autor: W. R. Simons, S. Kobina

Publikováno v: Journal of Clinical Oncology. 29:e16623-e16623

e16623 Background: The availability of newer therapeutic options to treat patients with cancer often depend on falling at or below economic value thresholds; namely, dollars per quality adjusted li...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68f38d881cd730d0b8419373550ef5f9
https://doi.org/10.1200/jco.2011.29.15_suppl.e16623

Zobrazit plný text záznamu

Phase II study of docetaxel and oxaliplatin in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer (NSCLC)

Autor: M. G. Perdekamp, M. Karr, S. Kobina, Edgardo S. Santos, Luis E. Raez, R. Brito

Publikováno v: Journal of Clinical Oncology. 28:e18022-e18022

e18022 Background: Docetaxel (D) is active in advanced NSCLC. Bevacizumab (B) enhances conventional chemotherapy with increased response rate and prolonged survival. The study objective is to evalu...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e52c0c63e7dddc01c712e3656a042ca3
https://doi.org/10.1200/jco.2010.28.15_suppl.e18022

Zobrazit plný text záznamu

A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded)

Autor: K. Kojouri, D. Bradford, S. Kobina, Mark A. Socinski, Rafat Ansari, J. K. Choksi, Kendrith M. Rowland, G. Gross

Publikováno v: Journal of Clinical Oncology. 26:19077-19077

19077 Background: Platinum-based doublets are the standard of care for advanced and metastatic NSCLC; however many patients (pts) can not tolerate side effects of this combination. This study was d...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c0d03b072813697f88eda5bd5daa99d
https://doi.org/10.1200/jco.2008.26.15_suppl.19077

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání